1. Home
  2. Community
  3. Promotions

  4. Immune-Humanized Mouse: Challenges and Solutions in Preclinical Evaluation of Oncology Drugs

Abstract

To overcome the translational limitation of using immunodeficient mouse model for evaluating oncology therapeutics, in this webinar, we introduce huHSC-NKG-ProF mice – a fully immune-humanized model capable of generating diverse human immune cells. For the studies involving tumor vaccines, ADCC-based therapies, and others, the model can enhance clinical relevance by offering more predictive insights into drug efficacy and safety.

Meet the Speaker
Joyce Yu, Ph.D.
Dr. Joyce Yu, an immunology expert with over 8 years of experience in tumor immunology, leads the development and application of humanized mouse models at Cyagen. She specializes in advancing preclinical models for immunotherapy research.
Who Should Attend
This webinar is designed for professionals involved in:
  • Tumor biology and immuno-oncology research
  • Preclinical evaluation of cancer therapies
  • Development of tumor vaccines and immune-based drugs
Recommended Background:
  • PhD/Master’s level researchers
  • From academia, biotech, or pharmaceutical industry
  • Experience in oncology or immunology fields preferred
What You’ll Learn
  • The key limitations of current immunodeficient mouse models in oncology studies
  • How huHSC-NKG-ProF mice improve immune reconstitution and translational relevance
  • Practical applications of this model in ADCC drug mechanisms, tumor vaccine testing, and immunotherapy combinations
  • Cyagen’s capabilities in supporting CRO services for oncology drug evaluation
Webinar Details
  • Date: April 24, 2025
  • Time: 9:00 AM (PDT) | 12:00 PM (EDT) | 6:00 PM (CET)
  • Format: Live Webinar (with Q&A)
  • Language: English
  • Duration: ~45 mins + 15 mins Q&A
Don’t miss this opportunity to explore the next-generation preclinical model for oncology research!